Related Experiment Videos
Controlled trial of aspirin in cerebral ischemia
Insights
Aspirin showed benefits in reducing combined endpoints of death, infarction, or transient ischemic attacks (TIAs) in patients with carotid artery disease. However, aspirin did not significantly prevent stroke or death alone.
Area of Science:
- Neurology
- Cardiovascular Medicine
- Clinical Trials
Background:
- Cerebral ischemia, often caused by carotid artery disease, poses a significant risk for stroke.
- Transient ischemic attacks (TIAs) are critical warning signs for impending stroke.
- Aspirin's antiplatelet properties suggest potential benefits in preventing ischemic events.
Observation:
- A double-blind trial involving 178 patients with carotid TIAs was conducted over 37 months.
- Patients received either aspirin or placebo, with follow-up for TIAs, death, cerebral infarction, or retinal infarction.
- The study excluded patients who had undergone carotid surgery prior to randomization.
Findings:
- Aspirin demonstrated a statistically significant reduction in a combined endpoint including death, cerebral/retinal infarction, and TIAs within the first six months.
- This benefit was most pronounced in patients with a history of multiple TIAs and appropriate carotid lesions.
- When endpoints were restricted to death or cerebral/retinal infarction, no statistically significant difference was observed between aspirin and placebo.
Implications:
- Aspirin may be beneficial in managing patients at high risk for recurrent ischemic events, particularly those with specific carotid pathologies.
- The study highlights the importance of defining specific endpoints in clinical trials for cerebral ischemia.
- Further research is needed to clarify aspirin's role in stroke prevention when considering infarction and death as isolated endpoints.
Abstract:
Adouble-blind trial of aspirin for the treatment of cerebral ischemia was begun in 1972 and continued for 37 months. This was accomplished despite difficulties in controlling a long-term study of a drug which has widespread availability and consumption. The study design, criteria for selection of patients, follow-up surveillance, and methods of data analysis are presented. We report only subjects without carotid surgery before randomization. Patients (178) who had carotid transient ischemic attacks (TIAs) were randomly allocated to aspirin or placebo and followed to determine the incidence of subsequent TIAs,death, cerebral infarction or retinal infarction. Analysis of the first six months of follow-up revealed a statistically significant differential in favar of aspirin when death or cerebral or retinal infarction and the occurrence of TIAs were grouped and considered together as end points. Significance in favor of aspirin treatment was mainly revealed in patients with a history of multiple TIAs and was most evident in those individuals having carotid lesions appropriate to the TIA symptoms. It cannot be inferred from this study that aspirin prevents stroke because when end points were restriced to death or cerebral or retinal infarction, there was no statistically significant differential between the aspirin and placebo treatments.